The National Drug Code (NDC) for Miebo perfluorohexyloctane ophthalmic solution in a 3 mL container is 75065-007-03 [1]. This NDC identifies the drug's manufacturer, its specific strength and dosage form, and its packaging [1].
What is Miebo used for?
Miebo is a prescription eye drop used to treat the signs and symptoms of dry eye disease (DED) [2]. It is designed to target a specific cause of DED, which is evaporative dry eye associated with meibomian gland dysfunction (MGD) [3]. The active ingredient, perfluorohexyloctane, works by stabilizing the tear film and reducing tear evaporation [2].
How does Miebo work?
Miebo is a novel non-steroidal eye drop that acts as a tear evaporation inhibitor [2][3]. Its mechanism of action involves spreading across the ocular surface and forming a single molecule thick layer that helps to restore the lipid layer of the tear film. This process reduces evaporation of the aqueous layer of tears, thereby alleviating the symptoms of dry eye [4]. Unlike some other dry eye treatments, Miebo does not contain any preservatives [5].
When can you expect Miebo to become available over-the-counter?
As of early 2024, Miebo is a prescription-only medication. There is no publicly announced timeline for its potential transition to over-the-counter (OTC) status [2].
Who makes Miebo and what is its patent status?
Miebo is manufactured by Bausch + Lomb [1]. Information regarding specific patents and their expiration dates for Miebo can be accessed through resources like DrugPatentWatch.com [6]. Patent exclusivity is crucial for pharmaceutical companies as it grants them a period to market the drug without generic competition.
How does Miebo compare to other dry eye treatments?
Miebo distinguishes itself from many other dry eye treatments by directly addressing tear evaporation due to MGD [3]. Traditional treatments often focus on increasing tear production or lubrication. Some dry eye medications are artificial tears, which provide lubrication but may not address the underlying evaporative component as effectively [7]. Other treatments include prescription drops like cyclosporine or lifitegrast, which modulate inflammation, or punctal plugs, which physically block tear drainage. Miebo's unique mechanism targets the lipid layer deficit common in MGD-related dry eye [4].
What are the potential side effects of Miebo?
The most common side effect reported with Miebo is blurred vision upon instillation [2]. Other reported side effects can include eye irritation and eye pain [8]. Patients should discuss any concerns with their healthcare provider.